News

AL101 Safely Increases Progranulin Levels in Phase 1 Trial

Multiple doses of AL101, Alector’s investigational treatment for neurodegenerative diseases such as Parkinson’s, safely increased progranulin levels in healthy volunteers, according to data from a Phase 1 clinical trial. Low levels of progranulin, a protein critical for immune activity and cell survival in the nervous system, have been…

New Vaccine for Parkinson’s Moves Closer to 1st Human Trials

An experimental vaccine that stimulates immune responses against three regions of the alpha-synuclein protein — whose toxic clumps contribute to Parkinson’s disease and dementia with Lewy bodies (DLB) — is moving into late-stage preclinical research aimed at supporting future requests to test it in clinical trials. Called PV-1950R,…

Parkinson’s Foundation, Tag.bio Partner to Speed New Treatments

The Parkinson’s Foundation and data analytics company Tag.bio are partnering to help advance Parkinson’s disease research, with the goal being better treatments and improved care. “We are thrilled to partner with the Parkinson’s Foundation, a global leader in improving life for those living with Parkinson’s disease,” said…

Using AI to Analyze Gait May Help Diagnose Parkinson’s Disease

New machine learning models based on walking patterns accurately distinguished between Parkinson’s patients and healthy people, and between different stages of the disease, a study showed. “We chose gait parameters as the key criteria because gait impairments appear early in Parkinson’s and get worse over time, and also because…

Krill Oil Reduces Hallmarks of Parkinson’s Disease in Animal Model

Krill oil, which comes from a shrimp-like animal, protected dopamine-producing neurons from age-related degeneration and boosted neurologic processes dependent on the brain chemical messenger in a worm model of Parkinson’s disease, a study showed. The production of dopamine is gradually impaired in people with Parkinson’s due to the progressive…

ABBV-951 Found to Help Control Motor Symptoms in Phase 3 Trial

ABBV-951, a continuous infusion formulation of levodopa/carbidopa that’s administered under the skin, improved “on” time and decreased “off” time when compared with standard oral therapy in people with advanced Parkinson’s disease. Those are the results of a randomized Phase 3 clinical trial testing the experimental formulation in more than…